US Bancorp’s iTeos Therapeutics ITOS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-149
| Closed | -$1.49K | – | 4154 |
|
|
2025
Q2 | $1.49K | Sell |
149
-487
| -77% | -$3.92K | ﹤0.01% | 3909 |
|
|
2025
Q1 | $3.8K | Sell |
636
-16,283
| -96% | -$120K | ﹤0.01% | 3732 |
|
|
2024
Q4 | $130K | Buy |
16,919
+4,843
| +40% | +$41.6K | ﹤0.01% | 2267 |
|
|
2024
Q3 | $123K | Buy |
12,076
+8,129
| +206% | +$124K | ﹤0.01% | 2293 |
|
|
2024
Q2 | $58.6K | Sell |
3,947
-2,578
| -40% | -$36.9K | ﹤0.01% | 2590 |
|
|
2024
Q1 | $89K | Sell |
6,525
-2,465
| -27% | -$26.9K | ﹤0.01% | 2426 |
|
|
2023
Q4 | $98.4K | Buy |
8,990
+8,902
| +10,116% | +$88.2K | ﹤0.01% | 2362 |
|
|
2023
Q3 | $964 | Sell |
88
-339
| -79% | -$4.33K | ﹤0.01% | 3773 |
|
|
2023
Q2 | $5.65K | Buy |
427
+168
| +65% | +$2.4K | ﹤0.01% | 3450 |
|
|
2023
Q1 | $3.52K | Buy |
+259
| New | +$4.64K | ﹤0.01% | 3632 |
|
|
2022
Q3 | – | Sell |
-1,017
| Closed | -$21K | – | 4139 |
|
|
2022
Q2 | $21K | Buy |
1,017
+760
| +296% | +$18K | ﹤0.01% | 3023 |
|
|
2022
Q1 | $8K | Buy |
257
+142
| +123% | +$5.16K | ﹤0.01% | 3455 |
|
|
2021
Q4 | $5K | Hold |
115
| – | – | ﹤0.01% | 3646 |
|
|
2021
Q3 | $3K | Buy |
+115
| New | +$3.01K | ﹤0.01% | 3791 |
|
Other funds holding ITOS
US Bancorp's ITOS Position: Q3 2025 in Review
US Bancorp sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 149 shares — an estimated $1.49K sold.
US Bancorp first reported a position in ITOS in Q3 2021 and held it in 14 quarters. The position peaked at $130K in Q4 2024. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.
- US Bancorp reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
- US Bancorp sold 149 iTeos Therapeutics shares in Q3 2025, an estimated $1.49K.
- US Bancorp first reported a position in iTeos Therapeutics in Q3 2021 and held it in 14 quarters.
- US Bancorp's iTeos Therapeutics position peaked at $130K in Q4 2024.
- 1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.
Based on US Bancorp's 13F filing for Q3 2025, filed 12 Nov 2025.